DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 171 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $14,313,000 | -21.4% | 319,202 | 0.0% | 0.48% | -25.1% |
| Q4 2020 | $18,217,000 | +43.3% | 319,202 | +28.8% | 0.63% | +12.6% |
| Q3 2020 | $12,709,000 | +11.7% | 247,748 | +30.1% | 0.56% | +4.8% |
| Q2 2020 | $11,376,000 | +183.6% | 190,482 | +95.5% | 0.54% | +113.9% |
| Q1 2020 | $4,011,000 | -51.2% | 97,432 | -73.2% | 0.25% | -23.0% |
| Q2 2019 | $8,211,000 | -2.8% | 364,105 | 0.0% | 0.33% | -3.8% |
| Q1 2019 | $8,451,000 | -34.4% | 364,105 | -40.6% | 0.34% | -43.7% |
| Q4 2018 | $12,873,000 | -50.2% | 613,281 | -8.1% | 0.60% | -31.0% |
| Q3 2018 | $25,836,000 | +28.2% | 667,262 | +30.3% | 0.87% | +19.6% |
| Q2 2018 | $20,154,000 | +132.2% | 512,180 | +18.3% | 0.73% | +114.7% |
| Q1 2018 | $8,679,000 | -8.0% | 433,060 | +4.0% | 0.34% | -9.3% |
| Q4 2017 | $9,438,000 | +70.1% | 416,342 | +42.5% | 0.38% | +62.3% |
| Q3 2017 | $5,548,000 | – | 292,147 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $69,030,000 | 15.95% |
| SV Health Investors, LLC | 449,951 | $25,679,000 | 12.37% |
| Sunesis Advisors, LLC | 96,299 | $5,496,000 | 4.45% |
| Redmile Group, LLC | 4,437,968 | $253,275,000 | 3.07% |
| Consonance Capital Management LP | 484,671 | $27,660,000 | 2.58% |
| SECTORAL ASSET MANAGEMENT INC | 488,842 | $27,898,000 | 1.97% |
| Opaleye Management Inc. | 222,000 | $12,670,000 | 1.66% |
| Eversept Partners, LP | 246,240 | $14,052,917 | 1.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 38,620 | $2,204,000 | 1.28% |
| Avoro Capital Advisors LLC | 1,300,000 | $74,191,000 | 1.28% |